Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for.
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in.
NEEDHAM, Mass., Aug. 10, 2023 Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported. -Today at 08:02 am- MarketScreener
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid